Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.52 |
| ▸ | CTH | P32929 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 12/20 | 0.42 |
| ▸ | GIPR | P48546 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | GCG | P01275 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081919 | 0.85 | GCGR (0.59) | GCGRGIPRGCG | |
| SCHEMBL2643119 | 0.78 | GCGR (0.38) | GCGRGIPRALPL | |
| SCHEMBL9782907 | 0.74 | KDM1A (0.49) | ALDH1A1ALPLMEN1RAB9AKMT2A | |
| SCHEMBL22570093 | 0.74 | BCHE (0.51) | ALDH1A1ALPLMEN1RAB9AKMT2A | |
| SCHEMBL9782901 | 0.74 | KDM1A (0.49) | ALDH1A1ALPLMEN1RAB9AKMT2A | |
| SCHEMBL2988632 | 0.74 | GRIN2B (0.59) | ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL7751595 | 0.74 | GRIN2B (0.59) | ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL2988633 | 0.74 | GRIN2B (0.59) | ALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL13813539 | 0.70 | ALDH1A1 (0.45) | ALDH1A1ALPLMEN1RAB9AKMT2A | |
| SCHEMBL13799812 | 0.70 | HDAC1 (0.50) | ALDH1A1ALPLMEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PANK3 2811/4885CTH 2974/4885ALDH1A1 3968/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | PANK3 2811/4885CTH 2974/4885ALDH1A1 3968/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | PANK3 2811/4885CTH 2974/4885ALDH1A1 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.